Cell of Origin and Cancer Stem Cells in Tumor Suppressor Mouse Models of Glioblastoma

SHEILA R. ALCANTARA LLAGUNO, XUANHUA XIE, AND LUIS F. PARADA

Brain Tumor Center and Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065

Correspondence: paradal@mskcc.org

The cellular origins and the mechanisms of progression, maintenance of tumorigenicity, and therapeutic resistance are central questions in the glioblastoma multiforme (GBM) field. Using tumor suppressor mouse models, our group recently reported two independent populations of adult GBM-initiating central nervous system progenitors. We found different functional and molecular subtypes depending on the tumor-initiating cell lineage, indicating that the cell of origin is a driver of GBM subtype diversity. Using an *in vivo* model, we also showed that GBM cancer stem cells (CSCs) or glioma stem cells (GSCs) contribute to resistance to chemotherapeutic agents and that genetic ablation of GSCs leads to a delay in tumor progression. These studies are consistent with the cell of origin and CSCs as critical regulators of the pathogenesis of GBM.

Glioblastoma is the most aggressive and prevalent primary malignancy in the central nervous system (CNS). However, despite numerous advances in cancer therapy, these tumors remain incurable (Stupp et al. 2005). In recent years, large-scale genomic analyses have been used to stratify glioblastoma multiforme (GBM) based on gene expression signatures, driver mutations, copy number changes, and other molecular alterations that could reflect differing pathologic characteristics (TCGA 2008). The Cancer Genome Atlas (TCGA) analyses based on the above-mentioned criteria resolve GBM into four subtypes denoted mesenchymal, proneural, classical, and neural (Verhaak et al. 2010). Several groups have since reported various glioma subtyping schema based on newer molecular data and other criteria (Eckel-Passow et al. 2015; Ceccarelli et al. 2016). The clinical implications for therapeutic response of these genomic subclassifications, however, remain unclear.

GBM-INITIATING LINEAGES

The extensive cellular heterogeneity found within the adult mammalian brain affords a variety of cell types that could, in principle, give rise to malignant tumors. Our studies have progressively focused on stem and progenitor cells in the adult brain as attractive candidates for tumor origin based on self-renewal and proliferative potential that would provide an opportunity for the stochastic accumulation of the essential mutations required for malignant transformation. In the mouse, adult neural stem cells reside in the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone of the hippocampal dentate gyrus, where they produce neuronal progenitor cells (NPCs) that primarily give rise to new neurons

(Ming and Song 2011). In contrast, the widely dispersed oligodendrocyte progenitor cells (OPCs) represent a significant proportion of dividing cells in the adult brain and are the primary source of oligodendrocytes in both the developing and mature CNS (Nishiyama et al. 2009).

A TALE OF TWO TUMORS

Various genetically engineered mouse models (GEMMs) of brain tumors have been generated by onco-gene overexpression and/or deletion of tumor suppressors in various cell types of the brain. Our laboratory has applied the GEMM technology to drive GBM formation through ablation of three of the most commonly mutated genes in human GBM: *NF1* (neurofibromin 1), *TP53* (tumor protein P53), and *PTEN* (phosphatase and tensin homolog). Initially, we used a human glial fibrillary acidic protein (GFAP) promoter transgene construct (*hGfap-cre*) to drive Cre recombinase expression in the embryonic and adult stem cell niche to generate compound heterozygotes at the tumor suppressor loci. Fully penetrant GBM formation was accompanied by loss of heterozygosity for the tumor suppressors in the malignant tissue (Zhu et al. 2005). These studies were further refined by targeting the adult neural stem cell compartment using a *Nestin-creER^{T2}* transgene to ablate tumor suppressors and also generated GBM with 100% efficiency (Alcantara Llaguno et al. 2009). More recently, we used an *Ascl1-creERTM* transgene that targets two different populations of adult lineage-restricted CNS progenitors, the NPCs and OPCs. Adult bipotential progenitor-directed loss of *Nf1*, *Trp53*, and *Pten* in mice led to the development of two histologically and molecularly distinct GBM subtypes (Alcantara Llaguno et al. 2015). The type 1 GBM

is a more infiltrative, Gfap^{hi} tumor and is preferentially found in the dorsal brain. The type 2 GBM has a Gfap^{lo} signature and better defined tumor borders and is most frequently found in the ventral brain (Fig. 1). Histologic and genomic analyses showed that *Ascl1-creERTM*-driven type 1 GBMs resemble *Nestin-creER^{T2}*-driven tumors. In contrast, the type 2 GBMs resembled tumors that were generated through mutation of the three tumor suppressors with an OPC-specific Cre driver (*NG2-creERTM*).

Thus, at least two independent populations of GBM-initiating adult progenitors exist that, in the setting of identical driver mutations, give rise to GBM as determined by classic histopathological criteria. However, additional pathological, molecular, and morbidity assays reveal differing features for the two GBM types, indicating that the cell of origin contributes to GBM genomic profiles and resultant phenotypes. This was further illustrated when GBM derived from different tumor suppressor mouse models were found to be molecularly separable based on the lineage of the tumor-initiating cell, indicating that tumor cells have cell-of-origin memory and thus supporting the idea that the cell of origin is a determinant of GBM subtype (Alcantara Llaguno et al. 2015). Given these results, the variety of cell lineages and progenitor populations in the adult mammalian brain (Ming and Song 2011; Merkle et al. 2014) present the plausible scenario that yet additional to-be-defined GBM subtypes may exist (Fig. 1). Thus, the various populations of tumor-initiating cells may underlie a diversity of functional subtypes found in human GBM.

It has been reported that more differentiated cell types can give rise to GBM in mouse models (Bachoo et al. 2002; Friedmann-Morvinski et al. 2012). Although in the experimental setting this may be possible, it is unclear how fully differentiated, nondividing neurons or astrocytes might acquire successive transforming mutations in the natural setting. To date, the occurrence of dedifferentiation in adult postmitotic CNS cells and its physiologic relevance remains controversial. Additional work on this topic will be essential to understand these issues.

DEVELOPMENTAL MEMORY OF GBM CELLS

How does a divergent lineage, such as the OPC lineage, give rise to a CNS tumor that exhibits predominantly histologic astrocytic features? Recent work suggests a common developmental origin for stem cells and progenitors. For example, embryonic OPCs have been shown to generate not only oligodendrocytes but also protoplasmic astrocytes in the gray matter of the ventral forebrain (Nishiyama et al. 2009). This raises the possibility that embryonic identity can be reactivated during adult glioma development, which may allow previously bipotential OPCs to give rise to type 2–like astrocytomas. Moreover, recent data show that adult SVZ neural stem cells share a common lineage with embryonic stem cells that give rise to the cells of the cortex, striatum, and septum (Fuenzalba et al. 2015), suggesting that transformed stem cells or progenitors may exhibit a developmental memory that preferentially leads them to migrate to these dorsal forebrain regions, where type 1 tumors are prevalent.

HUMAN GLIOMAS AND THE CELL OF ORIGIN

When we transplanted type 1 and type 2 GBMs as intracranial allografts, the engrafted tumors retained their original primary histological features, and type 1 tumor-transplanted mice showed significantly shorter median survival compared to type 2 tumor-transplanted mice (Alcantara Llaguno et al. 2015). This raises the possibility that GBM prognosis may be defined not only by the sum of pathological characterization and molecular driver genes but equally or more so by the cell of origin in which the mutations arise.

Our results show that GBM can be stratified into functional subtypes in mouse models through initiation in different progenitor cells. Expansion of such approaches to include the larger spectrum of possible initiating driver mutations and additional progenitor lineages integrated

Figure 1. Two independent populations of glioblastoma multiforme (GBM)-initiating central nervous system (CNS) progenitors exist in the adult mouse brain. (Right) GBMs can be initiated by tumor suppressor mutations in adult neuronal progenitor cells (NPCs) and adult oligodendrocyte progenitor cells (OPCs), which give rise to histologically and molecularly distinct tumors. NPC-driven type 1 tumors are infiltrative gliomas mostly found in the dorsal brain, whereas OPC-driven type 2 tumors have more defined tumor borders prevalent in ventral brain regions. (Left) Lineage hierarchy of CNS cells: Multipotent CNS stem cells undergo asymmetric cell division to produce bipotent progenitor cells that give rise to lineage-restricted progenitors that differentiate into mature CNS cell types. Other potential unique subsets of adult progenitor lineages may give rise to additional GBM subtypes.

with existing genomic and clinical data should provide a more robust and complete picture of GBM. Should this lead to discovery of lineage or subtype-specific pathways that can be therapeutically targeted, it will allow functional stratification of patients into subgroups that may respond to more tailored therapies.

CANCER STEM CELLS IN GBM

The concept of the cancer stem cells (CSCs) relates to the hypothesis that some solid tumors may propagate in a hierarchical fashion in which a relatively quiescent tumor cell lies at the apex of the hierarchy. In such a model, the highly proliferating derivative tumor cells are limited in their self-renewal capacity and are not responsible for therapeutic resistance or tumor relapse. The CSC model was led by research in the hematopoietic system, where in-depth characterization has resulted in a toolkit of cell surface markers that distinguish between hematopoietic stem cells, progenitors, and differentiated cells, as well as their malignant derivatives (Bonnet and Dick 1997). In solid tumors, CSCs have been described in different organ cancers, including breast, prostate, pancreas, colon, skin, and brain (Hermann et al. 2007; Wang et al. 2009a; Pece et al. 2010; Chen et al. 2012a; Driessens et al. 2012; Schepers et al. 2012). However, faithful markers for CSCs in solid tumors are in infancy and most CSC assays for solid tumors rely on indirect surrogate approaches such as the limited repertoire of enrichment antibodies or transplantation assays that involve tissue dissociation, removal from microenvironment, and, in some cases, incubation with growth factor cocktails in vitro.

For GBM patients, survival has not improved significantly in the last several decades, suggesting that current treatment regimens fail to target the critical cells responsible for tumor growth. One explanation for this would be that GBM development and growth is hierarchical and that CSCs are impervious to current therapies. We have examined glioma stem cells (GSCs) in the context of a possible relationship with wild-type neural stem and progenitor cells, and their possible roles not only in tumor initiation and maintenance but also in therapy resistance and tumor recurrence.

Through genomic landscape studies, GBM core signaling pathways that may contribute to gliomagenesis have been proposed. Among them, the ARF/P53 pathway, the INK4A/RB pathway, the RTK pathway, and the NF- κ B pathway are frequently dysregulated (Chen et al. 2012b). These same pathways are known to play essential roles in wild-type neural stem cell self-renewal, proliferation, and survival (Groszer et al. 2006; Meletis et al. 2006; Hegedus et al. 2007). A variety of mouse models manipulating these pathways in neural stem/progenitor cells have been shown to efficiently form high-grade gliomas (Zhu et al. 2005, 2014; Ligon et al. 2007; Alcantara Llaguno et al. 2009; Wang et al. 2009b; Zheng et al. 2013). These studies pointed to a critical role for neural stem/progenitor cells in glioma formation. However, whether GSCs exist in most or all forms of GBMs remains unknown.

GSCs were first isolated from human GBM samples by fluorescence-activated cell sorting (FACS) using the CD133/Prominin1 antibody (Singh et al. 2003). However, subsequent studies reported contradictory results showing that CD133-negative cells also possess similar properties as CD133-positive cells, such as neurosphere formation in defined culture media and the ability to form transplanted tumors (Nishide et al. 2009; Holmberg Olausson et al. 2014). Other markers have also been reported to enrich for GSCs, including integrin α 6, CD44, CD15, and EphA3 (Son et al. 2009; Anido et al. 2010; Lathia et al. 2010; Day et al. 2013). Nevertheless, a thorough characterization of these potential GSC markers is still lacking. There are also a host of unanswered questions. Are these different GSC markers expressed in the same cells? How are they functionally related to GSC features? How do these markers relate to the traditional (primary versus secondary) and genomic (neural, proneural, mesenchymal, classical) classifications of GBM? Furthermore, different assays have been used to investigate the GSC features of primary or cultured cells. The gold standard in the field is to perform tumor cell transplantation assays in immunodeficient mice, requiring tumor cell dissociation and often with manipulation in culture outside the tumor microenvironment before transplantation. The study of GSCs studied in their native microenvironment may better reflect their biological properties. The use of spontaneous mouse GBM models afford a reproducible and reliable system to genetically identify and label GSCs, elucidate their unique features, and examine the critical mechanisms involved in tumor recurrence.

IN VIVO GBM CSC MODEL

To directly test the CSC hypothesis in GBM, we used the human GFAP-Cre (*hGfap-cre*)-driven mouse GBM model together with a *Nestin- Δ TK-GFP* transgene, validated to label adult neural stem cells in the SVZ. This same transgene also labels a subset of quiescent tumor cells in mouse model GBMs. The presence of thymidine kinase (TK) allows the ablation of dividing TK transgene-positive cells with gancyclovir (GCV). Administration of GCV into mutant mice carrying the *Nestin- Δ TK-GFP* transgene was shown to significantly prolong the life span of tumor-bearing mice (Chen et al. 2012a). In vivo tracing with BrdU analogs IdU and CldU indicated that they were resistant to temozolomide treatment and responsible for tumor recurrence. Combination treatment of GCV and temozolomide also efficiently eradicated the type 1 dorsal tumors. However, mutant mice still died from secondary type 2–like ventral tumors that developed concurrently with the type 1 dorsal tumors. This may have been caused by the widespread expression of the *hGfap-cre* transgene used to initiate the tumors. Hence, a more restricted and preferably inducible cre expression would be required to circumvent this problem. On the other hand, the development of a GSC reporter provided a powerful means by which we can extensively determine the properties of GSCs.

Figure 2. A restricted cell population in a spontaneous glioblastoma multiforme (GBM) mouse model is responsible for tumor recurrence after chemotherapy. (A) A cartoon depicts the heterogeneity of glioblastoma. Dark green cells represent the quiescent stem cells; yellow, red, and blue cells indicate the actively dividing cells with different proliferative potential; light green cells, which represent the bulk tumor cells, have exited the cell cycle. (B) Upon temozolomide (TMZ) treatment, most of the dividing cells are eradicated. (C) Quiescent stem-like cancer cells re-enter the cell cycle to repropagate the tumor. They can divide symmetrically to form more stem cells (self-renewal) or asymmetrically to generate more proliferative cells.

USING THE NESTIN-GFP TRANSGENE TO CHARACTERIZE GSCS

The ability to label a GSC population in spontaneous GBM *in vivo* with the *Nestin-ΔTK-GFP* transgene opens the possibility of performing a relatively unbiased analysis for potential markers. FACS sorting of the Nestin-GFP⁺ cells enriches a unique population of tumor cells derived from the mouse model. Whole transcriptome analysis between the GFP⁺ and GFP[−] cells will potentially lead to a list of candidate genes for marker identification. It can also provide insight into the molecular characteristics of quiescent GFP⁺ GSCs that can be used to design potential therapies. One potential issue in the CSC field is the resolution of the cellular and molecular data collected in different studies. The quiescent status of CSCs can affect the overall behavior of tumor cells significantly. For example, it might change the overall transcription level of GSCs. If this is the case, analysis of cells in the group level could be misleading. Advances in sequencing technologies and computational analysis have greatly reduced the cost and effort of studying biological events at the single-cell level.

Together with other single-cell technologies in DNA analysis, proteomics, and metabolomics, we will be able to draw a higher-resolution map for the unique features of GSCs to elucidate their various roles in tumor progression, maintenance, and resistance to therapies.

GSCS AND THERAPEUTIC RESISTANCE

How do GSCs contribute to resistance to current therapies? There could be several mechanisms at play. For example, like many normal stem cell populations, GSCs may have enhanced capacity to either block entry or efficiently export drugs. Certain membrane transporters, such as ABCG2, have been shown to be up-regulated in both normal stem cells and GSCs (Bleau et al. 2009), which may allow GSCs to pump out chemotherapeutic drugs like temozolomide. Another possibility is that GSCs harbor distinct features that current radiation and chemotherapy treatments are incapable of targeting. Most of these therapies were designed to act on dividing tumor cells. Hence, the less proliferative, the less likely these tumor cells will be effectively targeted by agents de-

signed to target cell proliferation (cell cycle, mitosis, or DNA replication components). In addition, the relatively slow progression to cell cycle for GSCs would minimize the degree of mutation suffered compared to highly proliferative cells that would incur greater DNA damage during multiple rounds of treatment as they progress through cell division. Our studies with the *Nestin-ΔTK-GFP* transgene indicate that the GSCs are primarily in a quiescent state and exhibit relative resistance to the effects of chemotherapy (Fig. 2A,B). After drug treatment, quiescent GFP⁺ GSCs re-enter the cell cycle to produce new cells that eventually repopulate the tumor (Fig. 2C). This leads to tumor recurrence after aggressive multimodal treatment that has been the norm in GBM patients. The challenge therefore is to identify CSC vulnerabilities. Such approaches can complement traditional therapies in order to effect more lasting tumor inhibition.

CONCLUSION

Our studies on tumor suppressor mouse models suggest important roles for the cell of origin and CSCs in the pathogenesis of glioblastoma. However, despite numerous advances, much remains to be accomplished to elucidate the various mechanisms involved. The direct link between cells of origin and CSCs is also not clear. Do cells of origin directly give rise to CSCs or is there a common pathway to CSCs, as in leukemias? How do these transformations occur? Do similar pathways govern tumor initiation, progression, and maintenance? What aspects of the cellular origin are maintained or acquired in CSCs? Do different functional GBM subtypes possess distinct GSC subsets? How can these be targeted? Continued research using animal and xenograft models as well as human data analysis will provide a clearer picture of their contributions in GBM formation, which will hopefully lead to better diagnostics and therapeutics for glioblastoma. The hope is that better functional stratification of GBM and direct targeting of GSCs will add to the direly needed armamentarium to prolong the lives of patients with GBM.

ACKNOWLEDGMENTS

This work was supported in part by Children's Tumor Foundation Young Investigator Award and National In-

stitutes of Health (NIH) T32 Postdoctoral Trainee support (2T32CA124334-06; PI: Jerry Shay) to S.R.A.L. X.X. is supported by the American Brain Tumor Association Fellowship. L.F.P. is an American Cancer Society Research Professor and recipient of NIH R01 grant CA131313-01A1 and Cancer Prevention and Research Institute of Texas Grant RP100782.

Disclosure of conflicts of interest: The authors report no potential conflicts of interest.

REFERENCES

- Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, Burns DK, Alvarez-Buylla A, Parada LF. 2009. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. *Cancer Cell* **15**: 45–56.
- Alcantara Llaguno SR, Wang Z, Sun D, Chen J, Xu J, Kim E, Hatanpaa KJ, Raisanen JM, Burns DK, Johnson JE, et al. 2015. Adult lineage-restricted CNS progenitors specify distinct glioblastoma subtypes. *Cancer Cell* **28**: 429–440.
- Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA, Prieto-Sanchez RM, Barba I, Martinez-Saez E, Prudkin L, et al. 2010. TGF- β receptor inhibitors target the CD44^{high}/ID1^{high} glioma-initiating cell population in human glioblastoma. *Cancer Cell* **18**: 655–668.
- Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, Tang Y, DeFrances J, Stover E, Weissleder R, et al. 2002. Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. *Cancer Cell* **1**: 269–277.
- Bleau AM, Huse JT, Holland EC. 2009. The ABCG2 resistance network of glioblastoma. *Cell Cycle* **8**: 2936–2944.
- Bonnet D, Dick JE. 1997. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med* **3**: 730–737.
- Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, et al. 2016. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. *Cell* **164**: 550–563.
- Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF. 2012a. A restricted cell population propagates glioblastoma growth after chemotherapy. *Nature* **488**: 522–526.
- Chen J, McKay RM, Parada LF. 2012b. Malignant glioma: Lessons from genomics, mouse models, and stem cells. *Cell* **149**: 36–47.
- Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensby KS, Jamieson PR, Bruce ZC, Lim YC, Offenhauser C, et al. 2013. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. *Cancer Cell* **23**: 238–248.
- Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C. 2012. Defining the mode of tumour growth by clonal analysis. *Nature* **488**: 527–530.
- Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, et al. 2015. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. *N Engl J Med* **372**: 2499–2508.
- Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, Singer O, Ellisman MH, Verma IM. 2012. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. *Science* **338**: 1080–1084.
- Fuentealba LC, Rompani SB, Parraguez JI, Obner K, Romero R, Cepko CL, Alvarez-Buylla A. 2015. Embryonic origin of postnatal neural stem cells. *Cell* **161**: 1644–1655.
- Groszer M, Erickson R, Scripture-Adams DD, Dougherty JD, LeBelle J, Zack JA, Geschwind DH, Liu X, Kornblum HI, Wu H. 2006. PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. *Proc Natl Acad Sci* **103**: 111–116.
- Hegedus B, Dasgupta B, Shin JE, Emmett RJ, Hart-Mahon EK, Elghazi L, Bernal-Mizrachi E, Gutmann DH. 2007. Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. *Cell Stem Cell* **1**: 443–457.
- Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. 2007. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. *Cell Stem Cell* **1**: 313–323.
- Holmberg Olausson K, Maire CL, Haidar S, Ling J, Learner E, Nister M, Ligon KL. 2014. Prominin-1 (CD133) defines both stem and non-stem cell populations in CNS development and gliomas. *PLoS One* **9**: e106694.
- Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswigs J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB, et al. 2010. Integrin alpha 6 regulates glioblastoma stem cells. *Cell Stem Cell* **6**: 421–432.
- Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M, Louis DN, Depinho RA, et al. 2007. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. *Neuron* **53**: 503–517.
- Meletis K, Wirta V, Hede SM, Nister M, Lundberg J, Frisen J. 2006. p53 suppresses the self-renewal of adult neural stem cells. *Development* **133**: 363–369.
- Merkle FT, Fuentealba LC, Sanders TA, Magno L, Kessaris N, Alvarez-Buylla A. 2014. Adult neural stem cells in distinct microdomains generate previously unknown interneuron types. *Nat Neurosci* **17**: 207–214.
- Ming GL, Song H. 2011. Adult neurogenesis in the mammalian brain: Significant answers and significant questions. *Neuron* **70**: 687–702.
- Nishide K, Nakatani Y, Kiyonari H, Kondo T. 2009. Glioblastoma formation from cell population depleted of Prominin1-expressing cells. *PLoS One* **4**: e6869.
- Nishiyama A, Komitova M, Suzuki R, Zhu X. 2009. Polydendrocytes (NG2 cells): Multifunctional cells with lineage plasticity. *Nat Rev Neurosci* **10**: 9–22.
- Pecce S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP. 2010. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. *Cell* **140**: 62–73.
- Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, Clevers H. 2012. Lineage tracing reveals Lgr5⁺ stem cell activity in mouse intestinal adenomas. *Science* **337**: 730–735.
- Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. 2003. Identification of a cancer stem cell in human brain tumors. *Cancer Res* **63**: 5821–5828.
- Son MJ, Woolard K, Nam DH, Lee J, Fine HA. 2009. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. *Cell Stem Cell* **4**: 440–452.
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* **352**: 987–996.
- TCGA. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* **455**: 1061–1068.
- Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell* **17**: 98–110.
- Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C,

- Shen MM. 2009a. A luminal epithelial stem cell that is a cell of origin for prostate cancer. *Nature* **461**: 495–500.
- Wang Y, Yang J, Zheng H, Tomasek GJ, Zhang P, McKeever PE, Lee EY, Zhu Y. 2009b. Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. *Cancer Cell* **15**: 514–526.
- Zheng S, Fu J, Vegesna R, Mao Y, Heathcock LE, Torres-Garcia W, Ezhilarasan R, Wang S, McKenna A, Chin L, et al. 2013. A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. *Genes Dev* **27**: 1462–1472.
- Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, Messing A, Parada LF. 2005. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. *Cancer Cell* **8**: 119–130.
- Zhu Z, Khan MA, Weiler M, Blaes J, Jestaedt L, Geibert M, Zou P, Gronych J, Bernhardt O, Korshunov A, et al. 2014. Targeting self-renewal in high-grade brain tumors leads to loss of brain tumor stem cells and prolonged survival. *Cell Stem Cell* **15**: 185–198.

Cold Spring Harbor Symposia on Quantitative Biology

Cell of Origin and Cancer Stem Cells in Tumor Suppressor Mouse Models of Glioblastoma

Sheila R. Alcantara Llaguno, Xuanhua Xie and Luis F. Parada

Cold Spring Harb Symp Quant Biol 2016 81: 31-36 originally published online November 4, 2016
Access the most recent version at doi:[10.1101/sqb.2016.81.030973](https://doi.org/10.1101/sqb.2016.81.030973)

References

This article cites 37 articles, 6 of which can be accessed free at:
<http://symposium.cshlp.org/content/81/31.full.html#ref-list-1>

Creative Commons License

This article is distributed under the terms of the
<http://creativecommons.org/licenses/by-nc/4.0/>, which permits reuse and
redistribution, except for commercial purposes, provided that the original
author and source are credited.

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in
the box at the top right corner of the article or [click here](#).

To subscribe to *Cold Spring Harbor Symposia on Quantitative Biology* go to:
<http://symposium.cshlp.org/subscriptions>